Global Ophthalmology Drugs Market 2017-2023: Ophthalmology

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
125
Global Ophthalmology Drugs Market 2017-2023: Ophthalmology Market is Forecast to Reach $35 Billion in 2023

Dublin, Dec. 07, 2017 (GLOBE NEWSWIRE) -- The "Global Ophthalmology Drugs Market to 2023 - Angiogenesis Inhibitors in wAMD Set to Retain High Market Share, While Expansive Pipeline for Glaucoma Leads the Research Landscape" report has been added to Research and Markets' offering.

Ophthalmology is a broad therapy area that consists of almost 100 disorders associated with the eyes and visual system, including such diseases as glaucoma, age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR) and dry eye syndrome (DES). Many of these disorders are progressive, and if left untreated can lead to severe visual impairment or even blindness. The ophthalmology market is forecast to grow at a compound annual growth rate (CAGR) of 6.7% till 2023 - with the majority of this growth expected to occur in the final four years of the forecast period. Of the five key indications within the therapy area - glaucoma, AMD, DME, DR and DES - glaucoma and AMD have the most active product pipelines. Despite the majority of pipeline activity being centered on these five key indications, there is also significant interest in developing products for other indications such as allergic conjunctivitis and retinitis pigmentosa. In 2017, Spark Therapeutics is expected to gain FDA approval for its orphan drug Voretigene Neparvovec, which is currently under development for retinitis pigmentosa and leber congenital amaurosis. If approved, it would not only be the first pharmacological treatment for an inherited retinal disease, but would also be the first gene therapy for any genetic disease to be approved by the FDA. Six of the eight most commercially successful companies in the ophthalmology therapy area are among the top 20 pharma companies, including Roche, Allergan and Novartis. However, across the forecast period ophthalmology revenue growth for these companies is anticipated to be either negative or lower than the therapy area average. This will be due in part to the fact that ophthalmology products account for only 5% of these companies' late-stage pipelines. At the same time, a number of small and specialized ophthalmology companies are expected to enter the market, including Santen and Aerie. Scope

  • The ophthalmology therapeutics market is forecast to reach $35 billion in 2023. What are the key market segments driving this growth?
  • The pipeline contains over 800 products. What molecule types and molecular targets are in the pipeline? What are the commercial prospects of promising late-stage products?
  • Despite specific drug classes such as angiogenesis inhibitors dominating the commercial landscape, there is a very high proportion of novel drug classes in the pipeline. Which drug classes account for the largest proportion of early-stage development, and how do clinical failure rates, clinical trial size and clinical trial duration differ by indication and molecular target?
  • Although they are dominant in the market, large biotech companies are anticipated to lose market share to specialty ophthalmology companies, which are much more active in the pipeline. Which of the leading companies will have the highest market share by 2023? Which new companies will enter the market?
  • What licensing and co-development deals have occurred within this therapy area since 2006?

Key Topics Covered:

1 Table of Contents 2 Introduction 2.1 Therapy Area Introduction 2.1.1 Glaucoma 2.1.2 Age-Related Macular Degeneration 2.1.3 Diabetic Retinopathy 2.1.4 Diabetic Macular Edema 2.1.5 Dry Eye Syndrome 2.2 Symptoms 2.3 Diagnosis 2.4 Etiology and Pathophysiology 2.4.1 Etiology 2.4.2 Pathophysiology 2.5 Co-morbidities and Complications 2.6 Prognosis 2.6.1 Glaucoma 2.6.2 Age-Related Macular Degeneration 2.6.3 Diabetic Retinopathy and Diabetic Macular Edema 2.6.4 Dry Eye Syndrome 2.7 Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 2.7.1 Glaucoma 2.7.2 Age-Related Macular Degeneration 2.7.3 Diabetic Macular Edema 2.7.4 Diabetic Retinopathy 2.7.5 Dry Eye Syndrome 2.8 Treatment 3 Key Marketed Products 3.1 Overview 3.2 Lucentis (ranibizumab) 3.3 Eylea (aflibercept) 3.4 Avastin (bevacizumab) 3.5 Restasis (cyclosporine) 3.6 Alphagan (brimonidine tartrate) 3.7 Lumigan (bimatoprost) 3.8 Xalatan (latanoprost) 3.9 Conclusion 4 Pipeline Landscape Assessment 4.1 Overview 4.2 Pipeline Development Landscape 4.3 Molecular Targets in the Pipeline 4.4 Clinical Trials 4.4.1 Failure Rate 4.4.2 Clinical Trial Duration 4.4.3 Clinical Trial Size 4.4.4 Aggregate Clinical Program Size 4.4.5 Assessment of Key Pipeline Products 4.4.6 Conclusion 5 Multi-Scenario Market Forecast to 2023 5.1 Overall Market Size 5.2 Generic Penetration 5.2.1 Angiogenesis Inhibitors (VEGF/PlGF/PDGF Inhibitors) 5.2.2 Antihistamines (Histamine H1 Receptor) 5.2.3 Anti-inflammatory Agents (Glucocorticoid Receptor/IL-1 Receptor/Prostaglandin Receptor) 5.2.4 IOP Modulators (Prostaglandins, Beta Blockers and the Rho Kinase Signaling Pathway) 6 Company Analysis and Positioning 6.1 Revenue and Market Share Analysis by Company 6.1.1 Novartis - Can the Approval of Fovista and Brolucizumab Offset Revenue Lost Following Patent Expirations? 6.1.2 Regeneron - Will Regeneron be Able to Retain its Position in the Ophthalmology Market across the Forecast Period with Eylea Alone? 6.1.3 Roche - To What Extent Will Pipeline Product Approvals Offset the Patent Expiries of Lucentis and Avastin? 6.1.4 Bayer - Can Bayer Retain its Position in the Ophthalmology Market Given its Small Product Portfolio and Ophthalmology Pipeline? 6.1.5 Allergan - How Will Declining Revenue from Restasis Affect Allergan's Overall Position within the Ophthalmology Therapy Area? 6.1.6 Shire - How Will Anticipated New Approvals Perform Across the Forecast Period? 6.1.7 Mallinckrodt - Will its Small Ophthalmology Portfolio and Limited Pipeline be Sufficient to Maintain the Position of Mallinckrodt in the Market? 6.1.8 Santen - Will Santen Continue to Rely on Ophthalmology Therapy Area for the Majority of its Company Revenue? 6.1.9 Aerie - Will Aerie be Able to Successfully Enter the Market with Two New Approvals? 6.2 Company Landscape 6.3 Marketed and Pipeline Portfolio Analysis 7 Strategic Consolidations 7.1 Licensing Deals 7.1.1 Deals by Region, Year and Value 7.1.2 Deals by Stage of Development and Value 7.1.3 Deals by Molecule Type, Mechanism of Action and Value 7.1.4 Table for Licensing Deals Valued Above $100m 7.2 Co-development Deals 7.2.1 Deals by Region, Year and Value 7.2.2 Deals by Stage of Development and Value 7.2.3 Deals by Molecule Type, Mechanism of Action and Value 7.2.4 Table for Co-development Deals Valued Above $100m 8 Appendix 8.1 References 8.2 Figures of All Clinical Stage Pipeline Products 8.3 Abbreviations 8.4 Disease List 8.5 Methodology 8.5.1 Coverage 8.5.2 Secondary Research 8.5.3 Market Size and Revenue Forecasts 8.5.4 Pipeline Analysis 8.5.5 Competitive Landscape

Companies Featured

  • Novartis
  • Regeneron
  • Roche
  • Bayer
  • Allergan
  • Shire
  • Mallinckrodt
  • Santen Therapeutics
  • Aerie

For more information about this report visit https://www.researchandmarkets.com/research/84gc2d/global

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Optical Disorders Drugs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 87

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
AI Gives CPA Firms a New Advisory Staffing Math Today

Updated Category News Views 26

Month-end just got a lot less comfortable for firms living on the clock. Netsurit and Southwestern Talent are pitching the Virtual CFO Platform as a way for CPA firms to turn machine-led analysis into advisory work without first building a costly bench of specialists. That is not a cute workflow tweak. It goes straight at the labor model that has kept plenty of accounting...

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 183

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 123

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 54

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
RayNeo's Black Friday Push Tests Smart Glasses Demand

Updated Category News Views 85

A million shipped pairs is a real milestone, but holiday markdowns are where the rubber meets the road for RayNeo. The company is taking its XR gaming glasses and iO AI smart glasses into Europe’s Black Friday scrum with discounts running through late November, betting that portability, giant virtual screens and a little AI convenience can pry open consumers’ wallets....

Continue Reading
Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 54

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
LEPAS AURA Signals a Sharper Design Bet for Future Cars

Updated Category News Views 31

A porcelain-smooth concept car is not a balance sheet, but it can tell you where a young automotive brand intends to spend its attention. LEPAS unveiled AURA in October at its first Global Elegant Lifestyle Week, presenting it as the brand's first global concept car and a fresh expression of its Leopard Aesthetics design language. That matters because AURA is plainly not...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 68

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 229

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading

Top 5 Most Recently Viewed Articles

Desreta Jackson's New Show: A Journey of Healing and Legacy

Updated Category News Views 551

Desreta Jackson Unveils Groundbreaking Show This Fall Desreta Jackson, who captivated audiences through her memorable role as young Celie in Steven Spielberg's acclaimed film The Color Purple, is set to make her return to the limelight with the launch of The Desreta Jackson Show this fall. Produced by Desicon Pictures, the show seeks to ignite meaningful conversations...

Continue Reading
Clarios Unveils Ambitious Initiative to Transform U.S. Manufacturing

Updated Category News Views 354

Clarios Set to Revolutionize U.S. Manufacturing Landscape Clarios is embarking on an exciting journey to bolster American manufacturing, with plans to establish a cutting-edge technology campus focusing on advanced supercapacitor systems production. This initiative is part of a comprehensive $6 billion investment strategy aimed at strengthening domestic supply chains....

Continue Reading
Franchise Equity Partners Expands with Strategic Valvoline Deal

Updated Category News Views 274

Franchise Equity Partners Forms Strategic Partnership with Valvoline Franchise Equity Partners (FEP) is thrilled to announce a new strategic partnership with Valvoline Inc. This collaboration marks a significant milestone as FEP plans to acquire 38 Valvoline company-owned stores. The stores, located in various regions of Texas, will be transitioning to a newly established...

Continue Reading
New Found Gold Announces Successful Financing Round Closing

Updated Category News Views 183

Recent Financing Success of New Found Gold New Found Gold Corp. (TSXV: NFG) (NYSE-A: NFGC) is excited to share the successful closing of its second and final tranche in the bought deal financing, securing a remarkable C$63 million to advance its projects. This milestone marks a significant achievement for the Company, facilitating crucial developments in the exploration...

Continue Reading
Joby Aviation Surpasses Expectations in Q3 Financials

Updated Category News Views 194

Joby Aviation's Remarkable Growth in Q3 Joby Aviation, Inc. (NYSE: JOBY) has recently experienced a substantial surge in stock value, reflecting investor confidence following the release of its third-quarter earnings report. This report highlighted significant movements, particularly as it beat estimates on revenue, even though it faced a mixed assessment regarding its...

Continue Reading